Kaleido Biosciences, Inc. KLDO

KLDO Company Overview

Kaleido Biosciences, Inc. (NASDAQ: KLDO) was a U.S.-based biotechnology company focused on developing microbiome-related therapeutics designed to modulate the metabolic activity of the human gut microbiome. The company operated within the biotechnology and life sciences industries, with a primary emphasis on microbiome science, metabolic health, and immunology. Kaleido’s core platform centered on microbiome metabolic therapies (MMTs), which were synthetic glycan compounds intended to selectively alter gut microbial function without introducing live organisms.

The company’s principal research programs targeted rare diseases and immune-related conditions, including sickle cell disease and COVID-19-related supportive therapies during portions of its operating history. Kaleido was founded in 2015 and emerged during a period of increased investment in microbiome therapeutics. The company completed an initial public offering in 2019 but later faced operational and financing challenges after clinical setbacks and limited commercialization prospects. Public filings indicate the company ultimately reduced operations significantly and pursued strategic alternatives before filing for Chapter 11 bankruptcy protection in 2022. Data regarding certain late-stage restructuring activities is limited across public sources.